Literature DB >> 25917663

Prevalence and Severity of Dysphonia in Patients with Cystic Fibrosis: A Pilot Study.

John Willis1, Deirdre D Michael1, Holly Boyer1, Stephanie Misono2.   

Abstract

OBJECTIVE: To assess the prevalence and severity of dysphonia in patients with cystic fibrosis sinusitis. We hypothesized that patients with CF sinusitis, compared with 2 control groups, would have higher self-reported prevalence of dysphonia and greater severity of dysphonia, according to patient-reported outcome measures as well as auditory-perceptual evaluation by expert listeners. STUDY
DESIGN: Cross-sectional comparative pilot study.
SETTING: Academic tertiary care clinic. STUDY PARTICIPANTS AND METHODS: Analysis included 37 study participants: 17 patients with CF sinusitis, 10 healthy individuals, and 10 patients with non-CF sinusitis. All participants completed the 10-item Voice Handicap Index (VHI-10) questionnaire and provided voice samples. On all samples, 6 blinded speech-language pathologists independently performed auditory-perceptual evaluation, using Consensus Auditory-Perceptual Evaluation of Voice. To assess severity of sinonasal symptoms, we used the 20-item Sinonasal Outcome Test (SNOT-20). Standard parametric and nonparametric statistical analysis was performed.
RESULTS: The differences between the 3 groups in prevalence of abnormal VHI-10 scores were not statistically significant. SNOT-20 scores were similar in the 2 sinusitis patient groups. VHI-10 scores were highest in patients with CF sinusitis, intermediate in patients with non-CF sinusitis, and lowest in healthy individuals (P = .005). Auditory-perceptual evaluation demonstrated greater overall severity of dysphonia in patients with CF sinusitis compared with the 2 control groups (P = .0005).
CONCLUSIONS: Cystic fibrosis sinusitis appeared to be associated with worse vocal function as measured by patient self-report as well as auditory-perceptual evaluation of voice compared with patients with non-CF sinusitis and healthy controls. Further investigation in this area is warranted. © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2015.

Entities:  

Keywords:  auditory-perceptual; chronic sinusitis; cystic fibrosis; dysphonia; sinusitis; voice handicap

Mesh:

Year:  2015        PMID: 25917663      PMCID: PMC5542043          DOI: 10.1177/0194599815581832

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  19 in total

1.  A cross-sectional survey of voice disorders among primary school teachers in Hong Kong.

Authors:  Sophie Yick-yu Lee; Xiang Qian Lao; Ignatius Tak-sun Yu
Journal:  J Occup Health       Date:  2010-09-30       Impact factor: 2.708

Review 2.  Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology.

Authors:  Michael S Benninger; Berrylin J Ferguson; James A Hadley; Daniel L Hamilos; Michael Jacobs; David W Kennedy; Donald C Lanza; Bradley F Marple; J David Osguthorpe; James A Stankiewicz; Jack Anon; James Denneny; Ivor Emanuel; Howard Levine
Journal:  Otolaryngol Head Neck Surg       Date:  2003-09       Impact factor: 3.497

3.  Does knowledge of medical diagnosis bias auditory-perceptual judgments of dysphonia?

Authors:  Tanya Eadie; Alicia Sroka; Derek R Wright; Albert Merati
Journal:  J Voice       Date:  2010-03-26       Impact factor: 2.009

4.  Consensus auditory-perceptual evaluation of voice: development of a standardized clinical protocol.

Authors:  Gail B Kempster; Bruce R Gerratt; Katherine Verdolini Abbott; Julie Barkmeier-Kraemer; Robert E Hillman
Journal:  Am J Speech Lang Pathol       Date:  2008-10-16       Impact factor: 2.408

5.  Habitual use of vocal fry in young adult female speakers.

Authors:  Lesley Wolk; Nassima B Abdelli-Beruh; Dianne Slavin
Journal:  J Voice       Date:  2011-09-14       Impact factor: 2.009

Review 6.  Perceptual evaluation of voice quality: review, tutorial, and a framework for future research.

Authors:  J Kreiman; B R Gerratt; G B Kempster; A Erman; G S Berke
Journal:  J Speech Hear Res       Date:  1993-02

7.  Establishing validity of the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V).

Authors:  Richard I Zraick; Gail B Kempster; Nadine P Connor; Susan Thibeault; Bernice K Klaben; Zoran Bursac; Carol R Thrush; Leslie E Glaze
Journal:  Am J Speech Lang Pathol       Date:  2010-08-25       Impact factor: 2.408

8.  Voice disorders in the general population: prevalence, risk factors, and occupational impact.

Authors:  Nelson Roy; Ray M Merrill; Steven D Gray; Elaine M Smith
Journal:  Laryngoscope       Date:  2005-11       Impact factor: 3.325

9.  Development and validation of the voice handicap index-10.

Authors:  Clark A Rosen; Annie S Lee; Jamie Osborne; Thomas Zullo; Thomas Murry
Journal:  Laryngoscope       Date:  2004-09       Impact factor: 3.325

Review 10.  Vocal fold surface hydration: a review.

Authors:  Ciara Leydon; Mahalakshmi Sivasankar; Danielle Lodewyck Falciglia; Christopher Atkins; Kimberly V Fisher
Journal:  J Voice       Date:  2008-12-25       Impact factor: 2.009

View more
  2 in total

1.  A comparison of symptoms and quality of life before and after nasal septoplasty and radiofrequency therapy of the inferior turbinate.

Authors:  Ann Helen Nilsen; Anne-Sofie Helvik; Wenche Moe Thorstensen; Vegard Bugten
Journal:  BMC Ear Nose Throat Disord       Date:  2018-01-26

2.  Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.

Authors:  Adam J Kimple; Brent A Senior; Edward T Naureckas; David A Gudis; Ted Meyer; Sarah E Hempstead; Helaine E Resnick; Dana Albon; Wayne Barfield; Margo McKenna Benoit; Daniel M Beswick; Eliza Callard; Shelagh Cofer; Veronica Downer; E Claire Elson; Angela Garinis; Ashleigh Halderman; Lisa Hamburger; Meagan Helmick; Michael McCown; Cameron J McKinzie; Hanna Phan; Kenneth Rodriguez; Ronald C Rubenstein; Ashley Severin; Gopi Shah; Ambika Shenoy; Brittney Sprouse; Frank Virgin; Bradford A Woodworth; Stella E Lee
Journal:  Int Forum Allergy Rhinol       Date:  2022-02-22       Impact factor: 5.426

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.